Sanchez Gaunt Capital Management’s Novartis NVS Stock Holding History

Sanchez Gaunt Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$470K	Buy	2,997 +19	+0.6%	+$2.85K	0.26%	109
2026 Q1	$455K	Buy	+2,978	New	+$456K	0.28%	103

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sanchez Gaunt Capital Management's NVS Position: Q2 2026 in Review

Sanchez Gaunt Capital Management increased its Novartis (NVS) stake by 0.64% in Q2 2026, buying an estimated $2.85K and bringing the position to 2,997 shares worth $470K. The position accounts for 0.26% of the portfolio, ranked #109.

Sanchez Gaunt Capital Management first reported a position in NVS in Q1 2026 and has held it in 2 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Sanchez Gaunt Capital Management held 2,997 shares of Novartis worth $470K as of Q2 2026.
Sanchez Gaunt Capital Management bought 19 Novartis shares in Q2 2026, an estimated $2.85K.
Novartis made up 0.26% of Sanchez Gaunt Capital Management's portfolio in Q2 2026, its #109 holding.
Sanchez Gaunt Capital Management first reported a position in Novartis in Q1 2026 and has held it in 2 quarters since.
1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Sanchez Gaunt Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.